With the growing availability of feline blood components, there has been increasing interest in compatibility testing before transfusion. [5] [6] [7] [8] [9] [10] The most well-recognized feline blood group is the AB system, consisting of the A, B, and AB blood types. It is well established that feline blood contains naturally occurring alloantibodies against absent AB blood group antigens, and therefore it is imperative that all cats receive type-specific blood. [11] [12] [13] More comprehensive compatibility testing before transfusion includes the major and minor cross-match which detect recipient antibodies to donor RBCs and donor antibodies to recipient RBCs, respectively. Currently, the cross-match test is only recommended as a standard of care before transfusion in previously transfused cats, however, this practice has been challenged in recent years. 1, 2, 13, 14 A novel RBC antigen, Mik, was discovered in a group of domestic short haired cats in 2007. 6 Four Mik-negative type A cats had an incompatible cross-match with 30 Mik-positive type A cats. 6 Furthermore, one such Mik-negative recipient had an acute, hemolytic transfusion reaction (HTR) after an AB type-matched RBC transfusion. 6 These results imply the presence of naturally occurring alloantibodies in feline blood which are not identified by conventional AB blood typing. Crossmatch before RBC transfusion is necessary for their detection.
In 2014, a significantly greater increase in the PCV after transfusion in cats that received type-specific cross-match compatible blood as compared with cats that received type-specific noncross-matched blood was retrospectively documented. 7 These results suggest there might exist a subclinical level of hemolysis in transfused RBCs because of undetected alloantibodies in uncross-matched blood transfusions.
However, markers of HTR such as changes in clinical variables during the transfusion period, plasma hemoglobin concentration [pHb] , and serum bilirubin after transfusion are not reported in this study. 7 Furthermore, because of its retrospective nature, the reported population was biased as the majority of cats in the noncross-matched group were transfusion-naïve, whereas the majority of cats in the cross-matched group had received previous RBC transfusions or had unknown transfusion history. 7 A prospective, randomized study is required to further investigate these findings.
The purpose of this study was to examine the effect of crossmatch before transfusion in transfusion naïve anemic cats on the incidence of acute immunologic transfusion reaction for up to 24 hours after transfusion. Transfusion efficacy, as measured by PCV increase from baseline per mL/kg of packed red blood cells (pRBCs) transfused, was also evaluated. We hypothesized that transfusion of cross-match and blood type compatible pRBCs would decrease the incidence of acute transfusion reactions (ATR) and result in an increased PCV after transfusion when compared to noncross-matched cats given blood type compatible pRBCs.
| M A TE RI A L S A ND M E TH ODS
The study protocol was approved by the Institutional Animal Care 
| Blood type identification
Blood type identification was performed in standardized fashion by trained laboratory or veterinary personnel using either the tube agglutination procedure or the card agglutination technique (RapidVet-H Feline Blood typing card, DMS Laboratories, Flemington, New Jersey)
as described previously. 18 
| Cross-match procedure
Trained laboratory personnel performed all major cross-match procedures in standardized fashion as reported previously 5, 19 to detect for both macroscopic and microscopic evidence of agglutination and hemolysis.
| Statistical analysis
Baseline descriptive statistics are presented as mean and standard devi- 
| RE S U L TS

| Demographics
A total of 48 cats met the inclusion criteria and were enrolled in the study. Twenty-four cats were randomized to the CM1 (24/48) and 24
to the CM-(24/48). The median age of the study population was 11 all of which were FNHTR. There was no significant difference in the incidence of any type of transfusion reaction between the CM1 and CM-groups (P 5 .16) or in the incidence of FNHTR between CM1
and CM-(P 5 .11). 
| PCV after transfusion
There was no significant difference in mean PCV after transfusion scaled to dose of pRBCs administered between the CM1 and CMtransfusions for any time point (Table 2 ).
Regression models were constructed to evaluate for independent predictors of PCV after transfusion at each time point and two significant linear regression models were established. A substantial part of the rationale for the suspicion of subclinical hemolysis secondary to unidentified RBC antigens in cats has been the finding of a less than expected PCV after transfusion, which has been recently evaluated as a marker of the efficacy of RBC transfusion. 1, 2, 7 An expected rise of 1% in the hematocrit (HCT) for each 1 mL/kg of pRBCs or 2 mL/kg of whole blood administered has been suggested. 2, 4, 13, 19 Retrospective evaluation of the effect of cross-match procedure on PCV after transfusion found an increase in PCV of only 0.78%/mL/kg pRBC in a group of uncrossmatched cats. 7 Our study had a similar result of an immediate increase in PCV of 0.62%/mL/kg and 0.75%/mL/kg for the CM-and CM1 groups, respectively. The finding that CM1 and CM-groups in our study did not significantly differ with respect to PCV after transfusion at any time point suggests that these lower than anticipated values are not secondary to incompatibilities between donor and recipient blood. Other explanations for lower than expected PCV after transfusion include inaccuracy of formulae used to calculate PCV increase, 16 repeated blood sampling, 20 ongoing loss or destruction of RBCs, or dilution via administration of asanguinous fluids. Additionally, PCV after transfusion is dependent on the HCT of the transfused unit of pRBCs. Standard practice for blood banking in human transfusion medicine in the United States is to achieve a HCT of 55%-65% for each unit of pRBCs. 21 This accomplishes standardization such that 1 unit of pRBCs in a human will increase the HCT by 1%/mL/kg. 22, 23 To our knowledge, the HCT of pRBC units from veterinary commercial blood banks has never been evaluated so based on our data and the data of others, extrapolation of these formulas to predict PCV after transfusion in cats could be inaccurate. 7 Future studies incorporating HCT of pRBC units on predicting 24 Use of this technique in a future pretransfusion study is warranted.
The current recommendation in human medicine is that the cross- Furthermore, transfusion of these incompatible units did not result in clinical or serological evidence of hemolysis. 15, 25 Therefore, the crossmatch might detect clinically insignificant antibodies in humans after conventional testing. In our study, 19% of all major cross-matches performed in transfusion-naïve cats in the CM1 group revealed an incompatibility. The inclusion of transfusion-naïve cats in this study controlled for previous exposure to foreign RBC antigens so all incompatibilities identified here were primary in nature. The results of a major cross-match are not commonly reported in transfusion-naïve cats so the significance of this finding is unclear. However, similar to findings in human transfusion medicine, the results of our study suggest that cross-match identified incompatibilities in transfusion naïve cats might not be clinically relevant. This conclusion is supported by the lack of a significant difference between CM1 and CM-groups with regards to PCV after transfusion and incidence of transfusion reactions.
Febrile nonhemolytic transfusion reaction was suspected in 10 cats in the overall population, which is higher than previously reported.
However, those numbers are derived from retrospective studies, which could have underestimated the occurrence of FNHTR. 1,2 The incidence of FNHTR should not be expected to differ between cross-matched or noncross-matched cats receiving blood products because both blood typing and the major cross-match do not detect incompatibilities between donor and recipient leukocytes. 5 Our results supported this concept as there was a similar incidence of FNHTR between CM-and CM1 groups.
Our study screened for subclinical hemolysis to detect for any acute HTR. Plasma hemoglobin of the transfused units of pRBC as well as each cat was measured at all time points before and after transfusion. Two units of pRBCs in each group had a mild increase in the pHb before transfusion. This is suspected to have had negligible clinical implication because none of the cats that received those units had evidence of hemolysis; however, 1 of these cats was only monitored for 12 hours after transfusion because of euthanasia, which could have precluded detection of hemolysis. The other three cats were monitored for the full 24 hours. Furthermore, these units were not likely to contribute to decreased efficiency of transfusion because 3 of the cats that received these units had a higher PCV (%/mL/kg) after transfusion than the overall population (data not shown).
One cat in the CM1 group had a suspected acute HTR. The HTR was characterized by a normal pHb before and after transfusion followed by a progressive increase in the 12 and 24 hours pHb after transfusion. This cat additionally had a drop in PCV from 34% to 22% at 24 hours after transfusion, as well as a new onset Heinz body anemia. Other causes of hemolysis in this cat were unlikely and included microbial contamination of the transfused unit, repeated blood sampling, underlying systemic disease or administration of drugs resulting in Heinz body hemolytic anemia, or hemolysis secondary to use of a mechanical delivery system. 20, 24, 26, 27 This suggests that the transfusion of a major cross-match compatible unit of pRBCs might not completely eliminate the risk of HTR. In fact, it has been shown that low titers of antibodies can be present below the threshold of major cross-match detection. 5, 6, 25, 28, 29 This therefore implies that the major cross-match test might not be sensitive enough to detect all pRBC antibody incompatibilities between donor and recipient cats, which precludes its value as a pretransfusion test. It is also possible that hemolysis can occur from antibodies in donor plasma, which would only be detected by performing a minor cross-match and would not be detected by the major cross-match. The utility of the minor cross-match should be evaluated in future prospective studies.
Surprisingly, PCV before transfusion was a significant independent predictor of change in PCV after transfusion in this study, such that PCV before transfusion was inversely related to PCV after transfusion.
This finding has been previously documented, 7 however in the prior study, the pretransfusion PCV of the cross-matched cats was
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significantly lower than that of the noncross-matched cats. This suggests that the effect of PCV before transfusion rather than the effect of cross-match could have contributed to the significant difference seen in PCV after transfusion between the groups. 7 The implications of this phenomenon are unclear as, to the authors' knowledge, there are no studies investigating this topic in the human or veterinary literature.
Many of the cats with the most severe anemia in our study likely suf- Future studies are warranted to further explore this topic. We were unable to collect data points at the 12 and 24 hours time after transfusion for some cats because of death, euthanasia, need for second RBC transfusion, or discharge from the hospital. It is possible that insufficient data at these time points could have masked a significant effect (type II error). However, this is considered unlikely because no effect was seen at the immediate or 1 hour after transfusion time periods and efficacy of a blood transfusion should not increase over time after the transfusion is finished. Biochemical profile, complete blood count, and urinalysis were not obtained after each transfusion to assess for variables consistent with hemolysis (ie, RBC morphology, total bilirubin, urine free Hb). Although [pHb] is an indicator of hemolysis, clinicopathologic data would have been helpful in supporting a diagnosis of AHTR or could have been used to investigate for other causes of hemolysis.
Additionally, aerobic and anaerobic blood cultures of the transfused units were not performed to rule out microbial contamination as a source of transfusion reaction.
Previous retrospective analyses have found no association of etiology of anemia on transfusion efficacy, similar to the results in our study. 1, 4, 7 However, the classification scheme used in our study could have oversimplified the complex, multifactorial disease processes of these cats, resulting in failure to identify a significant difference between individuals. Additionally, some cats were classified into multiple categories for etiology of anemia, which could have precluded the ability to individually assess the impact of each type of anemia on PCV after transfusion. Hemolytic anemia was also uncommon in our study so the impact of this category of anemia on transfusion efficacy should be further assessed. Furthermore, critically ill cats were excluded from this study based on urgent need for transfusion so the results of this study might not apply to all feline transfusions. Future studies with a homogenous anemic population of cats are warranted.
In conclusion, results of this prospective, randomized study do not support the major cross-match test before transfusion to increase efficacy of and to decrease adverse events associated with RBC transfusion in AB blood typed transfusion naïve cats. Until the discovery of clinically relevant feline RBC antigens in addition to the AB and Mik blood group systems, or the development of an accurate antibody screening test for transfusion-naïve cats, the major cross-match procedure could still be warranted. This is particularly true when AB blood typing is not available. While our data do not support the major crossmatch test before transfusion, others recommend cross-match when the Mik status of the donor and recipient cats are unknown. 
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